$25.78
2.90% yesterday
NYSE, Sep 10, 10:10 pm CET

Stevanato Group Spa Stock price

$25.84
+3.99 18.26% 1M
+3.24 14.34% 6M
+4.05 18.59% YTD
+5.73 28.49% 1Y
+7.61 41.74% 3Y
+6.17 31.37% 5Y
+6.17 31.37% 10Y
+6.17 31.37% 20Y
NYSE, Closing price Wed, Sep 10 2025
-0.71 2.67%

Key metrics

Basic
Market capitalization
$7.1b
Enterprise Value
$7.4b
Net debt
$375.3m
Cash
$110.2m
Shares outstanding
272.9m
Valuation (TTM | estimate)
P/E
44.6 | 41.3
P/S
5.3 | 5.0
EV/Sales
5.5 | 5.3
EV/FCF
negative
P/B
4.3
Dividends
DPS
$0.06
Yield 1Y | 5Y
0.2% | 0.2%
Growth 1Y | 5Y
7.1% | -
Payout 1Y | 3Y
12.1% | 10.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$1.3b | $1.4b
EBITDA
$244.7m | $348.9m
EBIT
$230.0m | $236.6m
Net Income
$157.4m | $170.6m
Free Cash Flow
$-75.0m
Growth (TTM | estimate)
Revenue
5.3% | 8.2%
EBITDA
5.1% | 53.9%
EBIT
6.2% | 11.8%
Net Income
9.5% | 23.8%
Free Cash Flow
75.1%
Margin (TTM | estimate)
Gross
28.8%
EBITDA
18.3% | 25.0%
EBIT
17.2%
Net
11.8% | 12.2%
Free Cash Flow
-5.6%
Financial Health
Equity Ratio
60.3%
Return on Equity
8.4%
ROCE
10.5%
ROIC
8.0%
Debt/Equity
0.3
More
EPS
$0.6
FCF per Share
$-0.3
Short interest
4.0%
Employees
6k
Rev per Employee
$230.0k
Show more

Is Stevanato Group Spa a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Stevanato Group Spa forecast:

13x Buy
76%
4x Hold
24%

Analyst Opinions

17 Analysts have issued a Stevanato Group Spa forecast:

Buy
76%
Hold
24%

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,340 1,340
5% 5%
100%
- Direct Costs 954 954
7% 7%
71%
386 386
1% 1%
29%
- Selling and Administrative Expenses 127 127
7% 7%
10%
- Research and Development Expense 24 24
38% 38%
2%
245 245
5% 5%
18%
- Depreciation and Amortization 15 15
9% 9%
1%
EBIT (Operating Income) EBIT 230 230
6% 6%
17%
Net Profit 157 157
9% 9%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Stevanato Group Spa directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stevanato Group Spa Stock News

Neutral
Seeking Alpha
one day ago
Stevanato Group S.p.A. (NYSE:STVN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Franco Stevanato - CEO & Executive Chairman Lisa Miles - Chief Communications & Investor Relations Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Great.
Neutral
Business Wire
9 days ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Tuesday, September 9, 2025, at 7:45 a.m. ET - The 23rd Annual Morgan Stanley Global Hea...
Neutral
Business Wire
about one month ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0...
More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office Italy
CEO Franco Stevanato
Employees 5,521
Founded 1996
Website www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today